AMENDED AND RESTATED CONSORTIUM AGREEMENTAmended and Restated Consortium Agreement • November 20th, 2020 • Centurium Capital Partners 2018, L.P. • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED CONSORTIUM AGREEMENT (this “Agreement”) is made and entered into as of November 19, 2020, by and among Beachhead Holdings Limited (“Beachhead”), Double Double Holdings Limited (“Double Double”), Point Forward Holdings Limited (“Point Forward,” and together with Beachhead, Double Double, and any of their respective Affiliates who becomes a party to this Agreement, collectively, “Centurium”), CITIC Capital China Partners IV, L.P., represented by its general partner CCP IV GP Ltd. (“CCCP IV”), 2019B Cayman Limited, an Affiliate of CCCP IV (“2019B Cayman” or “CITIC”), Parfield International Ltd. (“Parfield”), HH SUM-XXII Holdings Limited (“Hillhouse”), V-Sciences Investments Pte Ltd (“V-Sciences”), Mr. Joseph Chow (“Mr. Chow”), Biomedical Treasure Limited (“Biomedical Treasure”), Biomedical Future Limited (“Biomedical Future”) and Biomedical Development Limited (“Biomedical Development”), TB MGMT Holding Company Limited (“TB MGMT”), TB Executives Unity Holding Lim
